+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Point-of-Care Influenza Diagnostics Market Forecast to 2033- Product Image
Point-of-Care Influenza Diagnostics Market Forecast to 2033- Product Image
New

Point-of-Care Influenza Diagnostics Market Forecast to 2033

  • PDF Icon

    Report

  • 150 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 6189484
REQUEST CUSTOMIZATION
Description Jump to:
The global point-of-care influenza diagnostics market size was estimated at USD 415.56 million in 2024 and is projected to reach USD 709.52 million by 2033, growing at a CAGR of 6.14% from 2025 to 2033. Increasing global prevalence and severity of seasonal & zoonotic influenza outbreaks, growth in adoption of rapid POC tests, technological advancements in the influenza POC tests, and telehealth & home-based testing integration are key drivers of market growth.

For instance, in October 2023, the International Federation of Red Cross and Red Crescent Societies reported around a billion seasonal flu cases annually, including 3-5 million cases of severe illness, causing 290,000 to 650,000 respiratory deaths annually. Furthermore, in June 2024, F. Hoffmann-La Roche (Switzerland) received approval from the U.S. Food and Drug Administration (FDA) (Emergency Use Authorization (EUA)) for its cobas Influenza A/B & RSV nucleic acid test, an Influenza A multiplex real-time polymerase chain reaction (RT-PCR) assay on the cobas liat system. Producing results in just 20 minutes on a compact analyzer suitable for most healthcare settings, the test uses either a single nasopharyngeal or anterior nasal swab sample to confirm or rule out infection with influenza A and B viruses.

The rapid adoption of point-of-care (POC) tests is a significant factor fostering market growth. These rapid tests provide prompt results, often within minutes, allowing for timely diagnosis and treatment decisions for outpatient and urgent care settings. The convenience and ease of use of rapid influenza diagnostic tests (RIDTs) reduce reliance on centralized laboratories, reduce turnaround time, and improve patient outcomes. Furthermore, these tests are becoming more affordable and accessible, allowing their use in various healthcare settings, such as clinics, pharmacies, and emergency rooms. This shift towards decentralized testing is reinforced by ongoing technological advancements that improve the sensitivity and specificity of rapid tests. Therefore, healthcare providers are more likely to use POC testing as part of routine influenza management, driving market growth, particularly in North America and Europe, with growing adoption in Asia-Pacific markets.

Moreover, one revolutionary factor propelling market expansion is the combination of telehealth and home-based influenza testing. FDA-approved home flu test kits, which are frequently used with telehealth platforms that allow virtual consultations and real-time results transmission to healthcare professionals, have made it possible for people to perform quick diagnostics in the convenience of their own homes. For instance, in October 2024, the Healgen Rapid Check Flu A&B Antigen Test was authorized for sale by the US Food and Drug Administration. The test, available without a prescription and intended for people with respiratory symptoms, uses a nasal swab sample to provide COVID-19 and flu results at home in about 15 minutes. The test can identify proteins from influenza A and B (the viruses that cause the flu).

This integration supports public health initiatives by promoting early detection and isolation, which slows the spread of influenza, and improves patient convenience and testing accessibility. The COVID-19 pandemic made home-based diagnostics easier, raising awareness and acceptance of remote healthcare solutions.

Global Point-of-Care Influenza Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global point-of-care influenza diagnostics market based on test type, influenza strain, technology, end-use, and region:
  • Test Type Outlook (USD Million, 2021-2033)
  • Rapid Antigen Tests (RIDT)
  • Molecular Point-of-Care Tests
  • Biosensor-Based Tests
  • Others
  • Influenza Strain Outlook (USD Million, 2021-2033)
  • Influenza A
  • Influenza B
  • Influenza A & B Combined Tests
  • Technology Outlook (USD Million, 2021-2033)
  • Immunoassay-based
  • Molecular Diagnostics
  • Nanotechnology based Systems
  • Others
  • End-use Outlook (USD Million, 2021-2033)
  • Hospitals
  • Clinics
  • Homecare Settings
  • Others
  • Regional Outlook (USD Million, 2021-2033)
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Point-of-Care Influenza Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Test Type
1.1.1.2. Influenza Strain Segment
1.1.1.3. Technology Segment
1.1.1.4. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Influenza Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Point-of-Care Influenza Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Test Type
2.3. Influenza Strain Snapshot
2.4. Technology Snapshot
2.5. End Use Snapshot
2.6. Competitive Landscape Snapshot
Chapter 3. Point-of-Care Influenza Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increasing global prevalence and severity of seasonal and zoonotic influenza outbreaks
3.4.2. Growth in adoption of rapid POC tests
3.4.3. Technological advancements in the influenza POC tests
3.4.4. Telehealth & home-based testing integration
3.5. Market Restraint Analysis
3.5.1. High cost of advanced testing equipment
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. Point-of-Care Influenza Diagnostics Market: Test Type Estimates & Trend Analysis
4.1. Point-of-Care Influenza Diagnostics Market: Test Type Movement Analysis
4.2. Point-of-Care Influenza Diagnostics Market by Test Outlook (USD Million)
4.3. Rapid Antigen Tests (RIDT)
4.3.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.4. Molecular Point-of-Care Tests
4.4.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.5. Biosensor-Based Tests
4.5.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.6. Others
4.6.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Point-of-Care Influenza Diagnostics Market: Influenza Strain Estimates & Trend Analysis
5.1. Point-of-Care Influenza Diagnostics Market: Influenza Strain Movement Analysis
5.2. Point-of-Care Influenza Diagnostics Market by Influenza Strain Outlook (USD Million)
5.3. Influenza A
5.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.4. Influenza B
5.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Influenza A & B Combined Tests
5.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Point-of-Care Influenza Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Point-of-Care Influenza Diagnostics Market: Technology Movement Analysis
6.2. Point-of-Care Influenza Diagnostics Market by Technology Outlook (USD Million)
6.3. Immunoassay-based
6.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.4. Molecular Diagnostics
6.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Nanotechnology based Systems
6.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Others
6.6.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Point-of-Care Influenza Diagnostics Market: End Use Estimates & Trend Analysis
7.1. Point-of-Care Influenza Diagnostics Market: End Use Movement Analysis
7.2. Point-of-Care Influenza Diagnostics Market by End Use Outlook (USD Million)
7.3. Hospitals
7.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
7.4. Clinics
7.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Homecare Settings
7.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Others
7.6.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Point-of-Care Influenza Diagnostics Market: Regional Business Analysis
8.1. Regional Market Snapshot
8.2. North America
8.2.1. North America Point-of-Care Influenza Diagnostics Market Estimates and Forecast, 2021-2033 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.2.2.2. Key Country Dynamics
8.2.2.3. Regulatory Framework
8.2.2.4. Reimbursement Scenario
8.2.2.5. Competitive Scenario
8.2.3. Canada
8.2.3.1. Canada Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.2.3.2. Key Country Dynamics
8.2.3.3. Regulatory Framework
8.2.3.4. Reimbursement Scenario
8.2.3.5. Competitive Scenario
8.2.4. Mexico
8.2.4.1. Mexico Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.2.4.2. Key Country Dynamics
8.2.4.3. Regulatory Framework
8.2.4.4. Reimbursement Scenario
8.2.4.5. Competitive Scenario
8.3. Europe
8.3.1. Europe Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.2. UK
8.3.2.1. UK Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.2.2. Key Country Dynamics
8.3.2.3. Regulatory Framework
8.3.2.4. Reimbursement Scenario
8.3.2.5. Competitive Scenario
8.3.3. Germany
8.3.3.1. Germany Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.3.2. Key Country Dynamics
8.3.3.3. Regulatory Framework
8.3.3.4. Reimbursement Scenario
8.3.3.5. Competitive Scenario
8.3.4. Spain
8.3.4.1. Spain Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.4.2. Key Country Dynamics
8.3.4.3. Regulatory Framework
8.3.4.4. Reimbursement Scenario
8.3.4.5. Competitive Scenario
8.3.5. France
8.3.5.1. France Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.5.2. Key Country Dynamics
8.3.5.3. Regulatory Framework
8.3.5.4. Reimbursement Scenario
8.3.5.5. Competitive Scenario
8.3.6. Italy
8.3.6.1. Italy Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.6.2. Key Country Dynamics
8.3.6.3. Regulatory Framework
8.3.6.4. Reimbursement Scenario
8.3.6.5. Competitive Scenario
8.3.7. Denmark
8.3.7.1. Denmark Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.7.2. Key Country Dynamics
8.3.7.3. Regulatory Framework
8.3.7.4. Reimbursement Scenario
8.3.7.5. Competitive Scenario
8.3.8. Sweden
8.3.8.1. Sweden Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.8.2. Key Country Dynamics
8.3.8.3. Regulatory Framework
8.3.8.4. Reimbursement Scenario
8.3.8.5. Competitive Scenario
8.3.9. Norway
8.3.9.1. Norway Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.3.9.2. Key Country Dynamics
8.3.9.3. Regulatory Framework
8.3.9.4. Reimbursement Scenario
8.3.9.5. Competitive Scenario
8.4. Asia-Pacific
8.4.1. Asia-Pacific Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.2. Japan
8.4.2.1. Japan Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.2.2. Key Country Dynamics
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Scenario
8.4.2.5. Competitive Scenario
8.4.3. China
8.4.3.1. China Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.3.2. Key Country Dynamics
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Scenario
8.4.3.5. Competitive Scenario
8.4.4. India
8.4.4.1. India Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.4.2. Key Country Dynamics
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Scenario
8.4.4.5. Competitive Scenario
8.4.5. South Korea
8.4.5.1. South Korea Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.5.2. Key Country Dynamics
8.4.5.3. Regulatory Framework
8.4.5.4. Reimbursement Scenario
8.4.5.5. Competitive Scenario
8.4.6. Thailand
8.4.6.1. Thailand Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.6.2. Key Country Dynamics
8.4.6.3. Regulatory Framework
8.4.6.4. Reimbursement Scenario
8.4.6.5. Competitive Scenario
8.4.7. Australia
8.4.7.1. Australia Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.4.7.2. Key Country Dynamics
8.4.7.3. Regulatory Framework
8.4.7.4. Reimbursement Scenario
8.4.7.5. Competitive Scenario
8.5. Latin America
8.5.1. Latin America Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.5.2.2. Key Country Dynamics
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Scenario
8.5.2.5. Competitive Scenario
8.5.3. Argentina
8.5.3.1. Argentina Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.5.3.2. Key Country Dynamics
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Scenario
8.5.3.5. Competitive Scenario
8.6. MEA
8.6.1. MEA Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.6.2. South Africa
8.6.2.1. South Africa Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.6.2.2. Key Country Dynamics
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Scenario
8.6.2.5. Competitive Scenario
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.6.3.2. Key Country Dynamics
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Scenario
8.6.3.5. Competitive Scenario
8.6.4. UAE
8.6.4.1. UAE Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.6.4.2. Key Country Dynamics
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Scenario
8.6.4.5. Competitive Scenario
8.6.5. Kuwait
8.6.5.1. Kuwait Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
8.6.5.2. Key Country Dynamics
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Scenario
8.6.5.5. Competitive Scenario
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. New Product Launch
9.2.2. Partnerships
9.2.3. Acquisition
9.2.4. Collaboration
9.2.5. Funding
9.3. Key Company Market Share Analysis, 2024
9.4. Company Heat Map Analysis
9.5. Company Profiles
9.5.1. Abbott
9.5.1.1. Company Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Becton Dickinson (BD)
9.5.2.1. Company Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Danaher/Cepheid
9.5.3.1. Company Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Quidel Corporation, Inc
9.5.4.1. Company Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Qiagen
9.5.5.1. Company Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. F. Hoffmann-La Roche Ltd
9.5.6.1. Company Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Bio-Rad
9.5.7.1. Company Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. BioMerieux (Biofire/Idaho Technologies)
9.5.8.1. Company Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Diasorin (Focus Diagnostics)
9.5.9.1. Company Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Hologic
9.5.10.1. Company Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Thermo/Remel
9.5.11.1. Company Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
9.5.12. Fujirebio.
9.5.12.1. Company Overview
9.5.12.2. Financial Performance
9.5.12.3. Product Benchmarking
9.5.12.4. Strategic Initiatives
9.5.13. Visby Medical
9.5.13.1. Company Overview
9.5.13.2. Financial Performance
9.5.13.3. Product Benchmarking
9.5.13.4. Strategic Initiatives
9.5.14. Twist
9.5.14.1. Company Overview
9.5.14.2. Financial Performance
9.5.14.3. Product Benchmarking
9.5.14.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Point-of-Care Influenza Diagnostics Market, by Region, 2021-2033 (USD Million)
Table 4 Global Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 5 Global Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 6 Global Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 7 Global Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 8 North America Point-of-Care Influenza Diagnostics Market, by Country, 2021-2033 (USD Million)
Table 9 North America Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 10 North America Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 11 North America Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 12 North America Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 13 U.S. Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 14 U.S. Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 15 U.S. Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 16 U.S. Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 17 Canada Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033, (USD Million)
Table 18 Canada Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033, (USD Million)
Table 19 Canada Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033, (USD Million)
Table 20 Canada Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 21 Mexico Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 22 Mexico Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 23 Mexico Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 24 Mexico Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 25 Europe Point-of-Care Influenza Diagnostics Market, by Country, 2021-2033, (USD Million)
Table 26 Europe Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 27 Europe Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 28 Europe Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 29 Europe Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 30 UK Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 31 UK Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 32 UK Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 33 UK Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 34 Germany Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 35 Germany Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 36 Germany Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 37 Germany Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 38 France Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 39 France Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 40 France Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 41 France Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 42 Italy Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 43 Italy Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 44 Italy Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 45 Italy Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 46 Spain Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 47 Spain Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 48 Spain Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 49 Spain Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 50 Sweden Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 51 Sweden Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 52 Sweden Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 53 Sweden Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 54 Norway Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 55 Norway Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 56 Norway Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 57 Norway Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 58 Denmark Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 59 Denmark Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 60 Denmark Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 61 Denmark Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 62 Asia-Pacific Point-of-Care Influenza Diagnostics Market, by Country, 2021-2033, (USD Million)
Table 63 Asia-Pacific Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 64 Asia-Pacific Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 65 Asia-Pacific Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 66 Asia-Pacific Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 67 Japan Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 68 Japan Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 69 Japan Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 70 Japan Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 71 China Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 72 China Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 73 China Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 74 China Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 75 India Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 76 India Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 77 India Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 78 India Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 79 Australia Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 80 Australia Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 81 Australia Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 82 Australia Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 83 Thailand Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 84 Thailand Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 85 Thailand Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 86 Thailand Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 87 South Korea Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 88 South Korea Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 89 South Korea Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 90 South Korea Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 91 Latin America Point-of-Care Influenza Diagnostics Market, by Country, 2021-2033, (USD Million)
Table 92 Latin America Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 93 Latin America Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 94 Latin America Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 95 Latin America Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 96 Brazil Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 97 Brazil Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 98 Brazil Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 99 Brazil Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 100 Argentina Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 101 Argentina Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 102 Argentina Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 103 Argentina Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 104 MEA Point-of-Care Influenza Diagnostics Market, by Country, 2021-2033, (USD Million)
Table 105 MEA Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 106 MEA Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 107 MEA Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 108 MEA Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 109 South Africa Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 110 South Africa Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 111 South Africa Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 112 South Africa Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 113 Saudi Arabia Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 114 Saudi Arabia Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 115 Saudi Arabia Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 116 Saudi Arabia Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 117 UAE Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 118 UAE Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 119 UAE Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 120 UAE Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
Table 121 Kuwait Point-of-Care Influenza Diagnostics Market, by Test Type, 2021-2033 (USD Million)
Table 122 Kuwait Point-of-Care Influenza Diagnostics Market, by Influenza Strain, 2021-2033 (USD Million)
Table 123 Kuwait Point-of-Care Influenza Diagnostics Market, by Technology, 2021-2033 (USD Million)
Table 124 Kuwait Point-of-Care Influenza Diagnostics Market, by End Use, 2021-2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Market summary
Figure 4 Market segmentation & scope
Figure 5 Market size and growth prospects
Figure 6 Global Point-of-Care Influenza Diagnostics Market - Key market driver analysis
Figure 7 Global Point-of-Care Influenza Diagnostics Market - Key market restraint analysis
Figure 8 Penetration & growth prospect mapping
Figure 9 Global Point-of-Care Influenza Diagnostics Market - Porter’s analysis
Figure 10 Global Point-of-Care Influenza Diagnostics Market - PESTEL analysis
Figure 11 Global Point-of-Care Influenza Diagnostics Market: Test Type outlook key takeaways
Figure 12 Global Point-of-Care Influenza Diagnostics Market: Test Type movement analysis
Figure 13 Rapid Antigen Tests (RIDT) Market Estimates, 2021-2033 (USD Million)
Figure 14 Molecular Point-of-Care Tests Market Estimates, 2021-2033 (USD Million)
Figure 15 Biosensor-Based Tests Market Estimates, 2021-2033 (USD Million)
Figure 16 Others Market Estimates, 2021-2033 (USD Million)
Figure 17 Global Point-of-Care Influenza Diagnostics Market Technology outlook key takeaways
Figure 18 Global Point-of-Care Influenza Diagnostics Market: Technology movement analysis
Figure 19 Influenza A Point-of-Care Influenza Diagnostics Market Estimates, 2021-2033 (USD Million)
Figure 20 Influenza B Point-of-Care Influenza Diagnostics Market Estimates, 2021-2033 (USD Million)
Figure 21 Influenza A & B Combined Tests Point-of-Care Influenza Diagnostics Market Estimates, 2021-2033 (USD Million)
Figure 22 Global Point-of-Care Influenza Diagnostics Market: Technology outlook key takeaways
Figure 23 Global Point-of-Care Influenza Diagnostics Market: Technology movement analysis
Figure 24 Immunoassay-based Market Estimates, 2021-2033 (USD Million)
Figure 25 Molecular Diagnostics Market Estimates, 2021-2033 (USD Million)
Figure 26 Nanotechnology based Systems Market Estimates, 2021-2033 (USD Million)
Figure 27 Others Market Estimates, 2021-2033 (USD Million)
Figure 28 Global Point-of-Care Influenza Diagnostics Market: End Use outlook key takeaways
Figure 29 Global Point-of-Care Influenza Diagnostics Market: End Use movement analysis
Figure 30 Hospitals Market Estimates, 2021-2033 (USD Million)
Figure 31 Clinics Market Estimates, 2021-2033 (USD Million)
Figure 32 Homecare Settings Market Estimates, 2021-2033 (USD Million)
Figure 33 Others Market Estimates, 2021-2033 (USD Million)
Figure 34 Regional marketplace: Key takeaways
Figure 35 Global Point-of-Care Influenza Diagnostics Market: Regional movement analysis
Figure 36 North America Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 37 U.S. Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 38 Canada Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 39 Mexico Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 40 Europe Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 41 UK Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 42 Germany Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 43 France Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 44 Spain Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 45 Italy Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 46 Denmark Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 47 Sweden Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 48 Norway Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 49 Asia-Pacific Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 50 Japan Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 51 China Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 52 India Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 53 South Korea Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 54 Australia Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 55 Thailand Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 56 Latin America Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 57 Brazil Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 58 Argentina Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 59 MEA Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 60 South Africa Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 61 Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 62 UAE Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 63 Kuwait Point-of-Care Influenza Diagnostics Market, 2021-2033 (USD Million)
Figure 64 Strategy framework

Companies Mentioned

The companies profiled in this Point-of-Care Influenza Diagnostics market report include:
  • Abbott
  • Becton Dickinson (BD)
  • Danaher/Cepheid
  • Quidel Corporation
  • Qiagen
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad
  • BioMerieux (Biofire/Idaho Technologies)
  • Diasorin (Focus Diagnostics)
  • Hologic
  • Thermo/Remel
  • Fujirebio
  • Visby Medical
  • Twist

Table Information

Report AttributeDetails
No. of Pages150
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 415.56 Million
Forecasted Market Value ( USD ) by 2033 $ 709.52 Million
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region ?2025-2033? - Product Image

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region ?2025-2033?

  • Report
  • 146 Pages
  • Global
From
U.S. Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location (OTC, POC), By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By End-use (Decentralized Labs, Hospitals), And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location (OTC, POC), By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By End-use (Decentralized Labs, Hospitals), And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Middle East Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Infectious Diseases, Oncology, Prenatal Testing), by Technology, by Test Location, by End-use, by Country, and Segment Forecasts, 2025-2033 - Product Image

Middle East Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Infectious Diseases, Oncology, Prenatal Testing), by Technology, by Test Location, by End-use, by Country, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Middle East
From
EMEA Point-of-Care Diagnostics Market Size, Share & Trends Analysis Report by Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), by End-use (Clinics, Home), by Region (Europe, MEA), and Segment Forecasts, 2025-2033 - Product Image

EMEA Point-of-Care Diagnostics Market Size, Share & Trends Analysis Report by Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), by End-use (Clinics, Home), by Region (Europe, MEA), and Segment Forecasts, 2025-2033

  • Report
  • 136 Pages
  • Africa, Europe, Middle East Africa, Europe, Middle East
From
Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.